Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorMATHIEU, Laurent
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorBEURTON, Antoine
dc.contributor.authorROUGIER, Nicolas
dc.contributor.authorFLAMBARD, Maude
dc.contributor.authorGERMAIN, Christine
dc.contributor.authorPERNOT, Mathieu
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorOUATTARA, Alexandre
dc.date.accessioned2024-03-12T15:11:15Z
dc.date.available2024-03-12T15:11:15Z
dc.date.issued2023-11-09
dc.identifier.issn1477-111Xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/188725
dc.description.abstractEnThere are several types of surface treatments (coatings) aimed at improving the biocompatibility of cardiopulmonary bypass (CPB) circuit. Some coatings appear to require higher doses of heparin to maintain anticoagulation goals, and some of them might induce postoperative coagulopathy. In this study, we compared the amount of heparin required, postoperative bleeding, and inflammatory response according to three types of coatings. We retrospectively included 300 consecutive adult patients who underwent cardiac surgery with CPB and received one of three coatings (Phisio®, Trillium®, and Xcoating™). Our primary objective was to compare, according to coating, the amount of heparin required to maintain an ACT > 400s during CPB. Our secondary objectives were to compare postoperative bleeding for 48 h and CRP rate. Baseline characteristics were comparable between groups except for age and preoperative CRP. We did not find a significant difference between the 3 coatings regarding the amount of heparin reinjected. However, we found less postoperative bleeding with the Xcoating™ circuit compared to the Phisio® circuit (-149 mL [-289; -26.5]; = 0.02) and a lower elevation of CRP with the Phisio® circuit (2.8 times higher than preoperative CRP) compared to Trillium® (4.9 times higher) and Xcoating™ (6.4 times higher); < 10. The choice of coating did not influence the amount of heparin required during CPB; however, the post-CPB inflammatory syndrome may be impacted by this choice.
dc.language.isoENen_US
dc.subjectarticle clinique
dc.subject.enanticoagulation; biocompatible circuit coatings; blood products; perfusionist; postoperative bleeding
dc.title.enHeparin consumption and inflammatory response according to the coating of cardiopulmonary bypass circuits in cardiac surgery: A retrospective analysis.
dc.title.alternativePerfusionen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1177/02676591231215282en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed37944166en_US
bordeaux.journalPerfusionen_US
bordeaux.page2676591231215282en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-04501479
hal.version1
hal.date.transferred2024-03-12T15:11:17Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Perfusion&amp;rft.date=2023-11-09&amp;rft.spage=2676591231215282&amp;rft.epage=2676591231215282&amp;rft.eissn=1477-111X&amp;rft.issn=1477-111X&amp;rft.au=MATHIEU,%20Laurent&amp;BEURTON,%20Antoine&amp;ROUGIER,%20Nicolas&amp;FLAMBARD,%20Maude&amp;GERMAIN,%20Christine&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée